Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$247M |
| 2 |
Johnson & Johnson
JNJ
|
+$225M |
| 3 |
MON
Monsanto Co
MON
|
+$213M |
| 4 |
AET
Aetna Inc
AET
|
+$208M |
| 5 |
Broadcom
AVGO
|
+$176M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$227M |
| 2 |
Microsoft
MSFT
|
+$224M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$205M |
| 4 |
Nike
NKE
|
+$187M |
| 5 |
Pfizer
PFE
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.75% |
| 2 | Technology | 13.74% |
| 3 | Healthcare | 12.69% |
| 4 | Industrials | 11.51% |
| 5 | Consumer Discretionary | 8.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2551
Ollie's Bargain Outlet
OLLI
$4.58B
| $964K | ﹤0.01% |
33,900
-326,800
| -91% | -$9.43M |
|
2552
ePlus
PLUS
$2.34B
| $956K | ﹤0.01% |
33,200
-46,800
| -59% | -$1.21M |
|
|
BZUN
2553
Baozun
BZUN
$168M
| $954K | ﹤0.01% |
79,000
-16,700
| -17% | -$240K |
|
|
BGMS
2554
Bio Green Med Solution Inc
BGMS
$5.04M
| $953K | ﹤0.01% |
3
+1
| +50% | +$318K |
|
2555
Pixelworks
PXLW
$45.9M
| $953K | ﹤0.01% |
28,358
+1,741
| +7% | +$59K |
|
|
ESRX
2556
DELISTED
Express Scripts Holding Company
ESRX
| $952K | ﹤0.01% |
+13,839
| New | +$992K |
|
2557
Liberty Latin America Class A
LILA
$1.68B
| $950K | ﹤0.01% |
67,565
-247,605
| -79% | -$3.76M |
|
|
AIOT
2558
PowerFleet Inc
AIOT
$423M
| $948K | ﹤0.01% |
174,915
+3,100
| +2% | +$15.8K |
|
|
RPRX
2559
DELISTED
Repros Therapeutics Inc.
RPRX
| $946K | ﹤0.01% |
716,413
+49,300
| +7% | +$85.7K |
|
2560
Westlake Chemical Partners
WLKP
$764M
| $945K | ﹤0.01% |
43,647
+28,347
| +185% | +$608K |
|
2561
Ardelyx
ARDX
$1.01B
| $941K | ﹤0.01% |
66,300
+19,300
| +41% | +$274K |
|
|
TRIB
2562
Trinity Biotech
TRIB
$8.17M
| $941K | ﹤0.01% |
906
-677
| -43% | -$699K |
|
|
USDP
2563
DELISTED
USD PARTNERS LP
USDP
| $941K | ﹤0.01% |
59,566
+6,466
| +12% | +$90.2K |
|
|
MRVC
2564
DELISTED
MRV Communications Inc
MRVC
| $940K | ﹤0.01% |
115,300
-2,500
| -2% | -$23.5K |
|
|
XNET
2565
Xunlei
XNET
$325M
| $938K | ﹤0.01% |
242,900
-63,200
| -21% | -$289K |
|
2566
G-III Apparel Group
GIII
$1.42B
| $934K | ﹤0.01% |
+31,600
| New | +$918K |
|
|
VXRT
2567
DELISTED
Vaxart
VXRT
| $934K | ﹤0.01% |
69,000
+8,531
| +14% | +$130K |
|
2568
Turkcell
TKC
$4.68B
| $930K | ﹤0.01% |
+134,819
| New | +$986K |
|
2569
Mitek Systems
MITK
$875M
| $926K | ﹤0.01% |
150,649
+4,413
| +3% | +$28.8K |
|
2570
Weyco Group
WEYS
$430M
| $926K | ﹤0.01% |
29,600
-1,400
| -5% | -$39.2K |
|
2571
Patterson-UTI
PTEN
$4.31B
| $922K | ﹤0.01% |
34,238
+21,000
| +159% | +$519K |
|
|
DWCH
2572
DELISTED
Datawatch Corp
DWCH
| $921K | ﹤0.01% |
167,400
+91,300
| +120% | +$605K |
|
|
GOLD
2573
Gold.com Inc
GOLD
$1.29B
| $917K | ﹤0.01% |
94,000
+29,800
| +46% | +$248K |
|
|
TNGO
2574
DELISTED
Tangoe, Inc.
TNGO
| $914K | ﹤0.01% |
116,000
-101,500
| -47% | -$836K |
|
|
ITG
2575
DELISTED
Investment Technology Group Inc
ITG
| $910K | ﹤0.01% |
46,100
-145,900
| -76% | -$2.64M |
|
Similar funds
Jim Simons's Q4 2016 Portfolio in Review
As of Q4 2016, Jim Simons held 3,715 positions worth $63.2B, up 12% from $56.6B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
Jim Simons deployed $5.07B of net new capital in Q4 2016, opening 418 new positions and adding to 1,792 existing holdings. Its largest new stake was Broadcom: 10,144,960 shares worth $179M.
By sector, the portfolio is most concentrated in Financials at 15% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $227M trimmed.
- Jim Simons's largest Q4 2016 buy was Broadcom: 10,144,960 shares worth $179M.
- Jim Simons added most to Gilead Sciences in Q4 2016, an estimated $247M increase.
- Jim Simons's biggest Q4 2016 reduction was Bristol-Myers Squibb, cutting an estimated $227M.
- Jim Simons fully exited Alphabet (Google) Class C in Q4 2016, selling an estimated $205M.
- Jim Simons's ten largest holdings make up 7.2% of its $63.2B portfolio in Q4 2016.
- Jim Simons opened 418 new positions and closed 494 in Q4 2016.
- Jim Simons's portfolio value rose 12% quarter-over-quarter to $63.2B.
Based on Renaissance Technologies's 13F filing for Q4 2016, filed 13 Feb 2017.